Forbion

Forbion is a European life sciences venture capital firm that co-led the $105m Series B fundraise for Tropic Biosciences alongside Corteva Catalyst. The Amsterdam-based firm specialises in therapeutics and, more recently, has extended its portfolio into agri-biotech and food technology, reflecting a convergence between pharmaceutical biology techniques and agricultural applications.

Founded in 2006 and managing over 2bn euros across multiple funds, Forbion typically invests in companies at the clinical-stage for therapeutics or commercial-readiness stage for agri-biotech. Its partners have backgrounds in pharmaceutical industry operations and academic research, giving it the scientific diligence capability to evaluate complex gene-editing approaches. The firm has offices in Naarden and Munich.

Forbions co-lead position alongside Corteva Catalyst in the Tropic round is strategically coherent: a financial life sciences specialist paired with an industry strategic provides Tropic with both independent scientific validation and commercial route-to-market expertise. For the UK agri-biotech sector, Forbion represents European specialist capital that is increasingly willing to back British companies, particularly those working in gene editing where UK post-Brexit regulatory flexibility is seen as a competitive advantage.